| Akt Inhibitor MK2206 studied in …STUDIED_INderived45 of 45show fewer |
|---|
| → studied in | NCT01480154Phase 1 · active not recruiting Akt Inhibitor MK2206 and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors, Melanoma, Prostate or Kidney Cancer · 45 trials list this drug (1 active) | — | — | Malignant Solid Neoplasm,Cutaneous Melanoma,Malignant Prostate Neoplasm+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01251861Phase 2 · completed Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer · 45 trials list this drug (1 active) | — | — | Malignant Prostate Neoplasm,Prostate Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01306045Phase 2 · completed Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies · 45 trials list this drug (1 active) | — | — | Thymus Carcinoma,Lung Non-Small Cell Carcinoma,Lung Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00963547Phase 1 · terminated A Study of MK-2206 in Combination With Trastuzumab and Lapatinib for the Treatment of HER2+ Solid Tumors (MK-2206-015) · 45 trials list this drug (1 active) | — | — | Solid Neoplasm,Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01307631Phase 2 · completed Akt Inhibitor MK2206 in Treating Patients With Recurrent or Advanced Endometrial Cancer · 45 trials list this drug (1 active) | — | — | Endometrial Adenocarcinoma,Endometrial Serous Adenocarcinoma,Endometrial Adenosquamous Carcinoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01248247Phase 2 · completed BATTLE-2 Program: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer · 45 trials list this drug (1 active) | — | — | Malignant Lung Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01258998Phase 2 · completed Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma · 45 trials list this drug (1 active) | — | — | Anaplastic Large Cell Lymphoma,Hairy Cell Leukemia,Non-Hodgkin Lymphoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00848718Phase 1 · completed A Phase I Study of MK-2206 in Combination With Standard Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors (MK-2206-003) · 45 trials list this drug (1 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01239342Phase 2 · terminated Akt Inhibitor MK2206 or Everolimus in Treating Patients With Refractory Kidney Cancer · 45 trials list this drug (1 active) | — | — | Kidney Carcinoma,Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01802320Phase 2 · completed Akt Inhibitor MK2206 in Treating Patients With Previously Treated Colon or Rectal Cancer That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery · 45 trials list this drug (1 active) | — | — | Colon Carcinoma,Colon Mucinous Adenocarcinoma,Colon Signet Ring Cell Adenocarcinoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01604772Phase 2 · completed Akt Inhibitor MK2206 in Treating Patients With Progressive, Recurrent, or Metastatic Adenoid Cyst Carcinoma · 45 trials list this drug (1 active) | — | — | Malignant Major Salivary Gland Neoplasm,Salivary Gland Carcinoma,Oral Cavity Adenoid Cystic Carcinoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00670488Phase 1 · completed Dose Escalation Study With MK-2206 in Patients With Locally Advanced or Metastatic Solid Tumors (MK-2206-002) · 45 trials list this drug (1 active) | — | — | Neoplasm,Malignant Neoplasm,Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01277757Phase 2 · completed Akt Inhibitor MK2206 in Treating Patients With Advanced Breast Cancer · 45 trials list this drug (1 active) | — | — | Malignant Breast Neoplasm,Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01253447Phase 2 · completed AKT Inhibitor MK-2206 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia · 45 trials list this drug (1 active) | — | — | Adult Acute Megakaryoblastic Leukemia,Adult Acute Myeloid Leukemia,Adult Acute Myeloid Leukemia with Maturation+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01243762Phase 1 · terminated A Study of Dalotuzumab + MK-2206, Dalotuzumab + MK-0752, and Dalotuzumab + Ridaforolimus Combination Therapies in Participants With Advanced Cancer (MK-0646-027) · 45 trials list this drug (1 active) | — | — | Malignant Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01021748Phase 1 · completed A Combination Therapy Study of MK-2206 and AZD6244 in Participants With Advanced Solid Tumors (MK-2206-010) · 45 trials list this drug (1 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01344031Phase 1 · completed MK2206 in Combination With Anastrozole, Fulvestrant, or Anastrozole and Fulvestrant in Treating Postmenopausal Women With Metastatic Breast Cancer · 45 trials list this drug (1 active) | — | — | Breast Neoplasm,Breast Carcinoma,Invasive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01776008Phase 2 · terminated Akt Inhibitor MK-2206 and Anastrozole With or Without Goserelin Acetate in Treating Patients With Stage II-III Breast Cancer · 45 trials list this drug (1 active) | — | — | Malignant Breast Neoplasm,Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01349933Phase 2 · completed Akt Inhibitor MK2206 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer · 45 trials list this drug (1 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01481129Phase 2 · completed Akt Inhibitor MK2206 in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma · 45 trials list this drug (1 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01369849Phase 1/Phase 2 · completed Akt Inhibitor MK2206, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma · 45 trials list this drug (1 active) | — | — | Chronic Lymphocytic Leukemia,Small Lymphocytic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01319539Phase 2 · terminated MK2206 in Treating Patients With Stage I, Stage II, or Stage III Breast Cancer · 45 trials list this drug (1 active) | — | — | Malignant Breast Neoplasm,Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01263145Phase 1 · completed MK2206 and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Metastatic Breast Cancer · 45 trials list this drug (1 active) | — | — | Adult Solid Neoplasm,Malignant Breast Neoplasm,Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01783171Phase 1 · completed Dinaciclib and Akt Inhibitor MK2206 in Treating Patients With Pancreatic Cancer That Cannot Be Removed by Surgery · 45 trials list this drug (1 active) | — | — | Pancreatic Carcinoma,Pancreatic Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01370070Phase 2 · completed MK-2206 in Recurrent Nasopharyngeal Carcinoma · 45 trials list this drug (1 active) | — | — | Nasopharyngeal Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01294306Phase 2 · completed MK2206 and Erlotinib Hydrochloride in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Progressed After Previous Response to Erlotinib Hydrochloride Therapy · 45 trials list this drug (1 active) | — | — | Lung Large Cell Carcinoma,Lung Non-Small Cell Carcinoma,Lung Squamous Cell Carcinoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01283035Phase 2 · completed A Phase II Study of Akt Inhibitor MK2206 in the Treatment of Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer · 45 trials list this drug (1 active) | — | — | Primary Peritoneal Carcinoma,Ovarian Carcinoma,Ovarian Sarcoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01425879Phase 2 · completed MK2206 in Treating Patients With Advanced Refractory Biliary Cancer That Cannot Be Removed by Surgery · 45 trials list this drug (1 active) | — | — | Adult Liver Carcinoma,Malignant Gallbladder Neoplasm,Adult Hepatocellular Carcinoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01249105Phase 2 · withdrawn MK-2206 for Recurrent Malignant Glioma · 45 trials list this drug (1 active) | — | — | Malignant Glioma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01658943Phase 2 · completed Selumetinib and Akt Inhibitor MK2206 or mFOLFOX Therapy Comprising Oxaliplatin and Fluorouracil in Treating Patients With Metastatic Pancreatic Cancer Previously Treated With Chemotherapy · 45 trials list this drug (1 active) | — | — | Malignant Pancreatic Neoplasm,Pancreatic Carcinoma,Pancreatic Acinar Cell Carcinoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01169649Phase 2 · completed Study of MK-2206 in Patients With Metastatic Neuroendocrine Tumors (NET) · 45 trials list this drug (1 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01260701Phase 2 · completed Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer · 45 trials list this drug (1 active) | — | — | Gastric Carcinoma,Gastric Diffuse Adenocarcinoma,Gastric Intestinal-Type Adenocarcinoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01186705Phase 2 · terminated Clinical And Translational Study Of MK-2206 In Patients With Metastatic KRAS-Wild-Type, PIK3CA-Mutated, Colorectal Cancer · 45 trials list this drug (1 active) | — | — | Malignant Colon Neoplasm,Malignant Rectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01239355Phase 2 · terminated MK2206 in Treating Patients With Advanced Liver Cancer That Did Not Respond to Previous Therapy · 45 trials list this drug (1 active) | — | — | Adult Liver Carcinoma,Hepatocellular Carcinoma,Adult Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01281163Phase 1 · terminated Lapatinib Ditosylate and Akt Inhibitor MK2206 in Treating Women With Metastatic Breast Cancer · 45 trials list this drug (1 active) | — | — | Malignant Breast Neoplasm,Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01295632Phase 1 · completed Safety and Tolerability of Different Dose Combinations of Ridaforolimus With MK-2206 or MK-0752 for Participants With Advanced Cancer (MK-8669-049) · 45 trials list this drug (1 active) | — | — | Malignant Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01245205Phase 1 · completed Akt Inhibitor MK2206 in Combination With Lapatinib Ditosylate in Patients With Advanced or Metastatic Solid Tumors or Breast Cancer · 45 trials list this drug (1 active) | — | — | Adult Solid Neoplasm,Malignant Breast Neoplasm,Male Breast Carcinoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01859182Phase 2 · withdrawn Selumetinib and Akt Inhibitor MK-2206 in Treating Patients With Refractory or Advanced Gallbladder or Bile Duct Cancer That Cannot Be Removed By Surgery · 45 trials list this drug (1 active) | — | — | Malignant Gallbladder Neoplasm,Malignant Extrahepatic Bile Duct Neoplasm,Adult Cholangiocarcinoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01466868Phase 2 · terminated Study of MK 2206 in Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma · 45 trials list this drug (1 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01519427Phase 2 · terminated Selumetinib and Akt Inhibitor MK2206 in Treating Patients With Stage III or Stage IV Melanoma Who Failed Prior Therapy With Vemurafenib or Dabrafenib · 45 trials list this drug (1 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01231919Phase 1 · completed MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia · 45 trials list this drug (1 active) | — | — | Childhood Solid Neoplasm,Hairy Cell Leukemia,Juvenile Myelomonocytic Leukemia+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01235897Phase 1 · completed MK-2206, Paclitaxel and Trastuzumab in Treating Patients With HER2-overexpressing Solid Tumor Malignancies · 45 trials list this drug (1 active) | — | — | Neoplasm,Malignant Neoplasm,Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01705340Phase 1 · terminated Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Metastatic HER2-Positive Breast , Gastric, or Gastroesophageal Cancer That Cannot Be Removed By Surgery · 45 trials list this drug (1 active) | — | — | Malignant Breast Neoplasm,Malignant Esophageal Neoplasm,Malignant Gastric Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01240941Phase 2 · withdrawn Trial of MK-2206 + Endocrine Treatment in Patients With Hormone Receptor Positive Breast Cancer · 45 trials list this drug (1 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01147211Phase 1 · unknown Dose Defining Study For MK-2206 Combined With Gefitinib In Non Small Cell Lung Cancer (NSCLC) · 45 trials list this drug (1 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |